In acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma, RHAMM activates cellular and humoral immune responses, and was thus chosen as a target for an anti-RHAMM peptide vaccination approach [27], which had some success in initial clinical trials. Here, HMMR is linked to myelodysplastic syndrome.